Physician profile
Flora Levin
NPI 1760683288
$19,227.59
in general payments reported to CMS, 2019-2025
7 companies · $9,177 in 2025
The $9,177 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $31.72 · 2021: $110 · 2022: $101 · 2023: $84.03 · 2024: $9,552 · 2025: $9,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,000.00 |
| Food and Beverage | $813.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $18,922.81 | 2019-2025 | |
| Merz North America, INC. | $81.73 | 2019-2020 | |
| Abbvie INC. | $69.56 | 2023-2024 | |
| Allergan, INC. | $59.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.27 | 2024-2025 | Entyvio |
| Organogenesis INC. | $21.98 | 2024 | Cygnus Dual |
| Kerecis Limited | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flora Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.